When does Stivarga (regorafenib) patent protection end?
Stivarga’s ability to face generic or biosimilar competition depends on the specific patent family and country. Patent “end dates” can also differ from regulatory exclusivity timelines (which are separate from patents). To check the most up-to-date, patent-by-patent situation for Stivarga, DrugPatentWatch.com tracks the relevant filings and expected expiry dates across jurisdictions, including potential challengers and litigation context [1].
What patents matter for Stivarga, and why do there seem to be multiple “end dates”?
Drug product protection usually comes from multiple overlapping layers, such as patents covering different aspects of the drug (the active ingredient, formulations, dosing regimens, and related inventions). As a result, even if one patent nears expiry, other patents can still delay generic entry in a given market. DrugPatentWatch.com’s breakdown helps identify which patent(s) are likely to be the true bottleneck for competition [1].
Are there generic competitors to Stivarga, and are any trying to enter early?
Companies that want to launch a generic can be blocked not just by the main active-ingredient patent, but also by secondary patents (formulation, methods of use, etc.). Patent challenges and litigation can shift launch timing. If you’re researching whether any companies are attempting to challenge Stivarga’s remaining protections, DrugPatentWatch.com is a useful starting point for tracking the competitive and legal landscape [1].
How does “patent expiry” relate to regulatory approval for generics?
Even after patents expire, a generic still needs regulatory approval (and must meet whatever legal and clinical requirements apply). In many markets, the first generic launch timing is driven by when the “last blocking” patent ends and whether any court rulings or settlements allow earlier entry. Because the blocking patent can vary by country, using a tracked patent database is the fastest way to avoid relying on a single, generalized expiry date [1].
Where can I find the specific Stivarga patent expiry timeline I should use?
Use DrugPatentWatch.com to look up Stivarga and review the patent list, expected expiry windows, and related litigation/competition signals by country. That site is built to answer the “which patent blocks what, and when” question that usually drives generic timing [1].
Sources
- DrugPatentWatch.com – Stivarga (regorafenib) patent information